Chromosome 15 carries roughly 600 protein-coding genes packed into about 3% of the human genome, and its outsized importance comes not from its size but from what those genes control. It houses the master regulatory region for genomic imprinting that gives rise to Prader-Willi and Angelman syndromes, the pigmentation genes that largely determine human eye color, the structural protein behind Marfan syndrome, the enzyme whose absence causes Tay-Sachs disease, and genes involved in heart muscle function, epilepsy risk, and leukemia. Few chromosomes punch this far above their weight.
Size, Shape, and Basic Layout
Chromosome 15 is one of the five acrocentric human chromosomes, meaning its centromere sits near one end rather than in the middle, giving it a very short arm (called 15p) and a much longer arm (15q). Its total physical size is estimated at about 107 million base pairs, with the short arm accounting for roughly 17 million and the long arm about 89 million.1Encyclopedia of Life Sciences. Chromosome 15 The short arm carries a cluster of ribosomal RNA genes, which are the molecular machinery cells use to build ribosomes and manufacture proteins. Those ribosomal gene clusters are shared across all five acrocentric chromosomes, and they are one reason why chromosome 15 sometimes participates in a type of structural rearrangement called a Robertsonian translocation, where two acrocentric chromosomes fuse at their short arms.2PubMed. Robertsonian translocations: mechanisms of formation, aneuploidy, and uniparental disomy and diagnostic considerations Compared with similarly sized chromosomes, chromosome 15 is relatively gene-poor overall, but the genes it does carry have an unusually high concentration of clinically significant roles.
Genomic Imprinting and Why Parent of Origin Matters
The single most distinctive feature of chromosome 15 is a stretch on its long arm, the 15q11-q13 region, that is subject to genomic imprinting. In most parts of the genome, both the copy you inherited from your mother and the copy from your father are active. Imprinted genes break that rule: one parental copy is chemically silenced, and only the other parent’s copy is expressed. Which copy stays on and which gets shut down depends on whether it came from the egg or the sperm.3PubMed. Neurodevelopmental disorders involving genomic imprinting at human chromosome 15q11-q13 The silencing happens through chemical tags, particularly DNA methylation, that are laid down during the formation of eggs and sperm and then maintained after fertilization.
This imprinting is controlled by a specific stretch of DNA called the imprinting centre, which acts as a switch for the entire region.4Genomic Imprinting. Imprinting in the Prader-Willi/Angelman syndrome region on human chromosome 15 The practical consequence is that if something goes wrong with the active copy of an imprinted gene, the silent copy on the other chromosome cannot step in as a backup. That vulnerability is what makes 15q11-q13 the site of two very different genetic disorders, depending on which parent’s contribution is lost.
Prader-Willi Syndrome
Prader-Willi syndrome arises when the paternal copy of genes in the 15q11-q13 region is missing or nonfunctional. Because the maternal copies of those same genes are normally silenced by imprinting, losing the paternal set leaves a person with effectively no working versions. In about 70% of cases, the cause is a deletion of a chunk of the father’s chromosome 15 in this region. In roughly 25% of cases, the child inherits two copies of chromosome 15 from the mother and none from the father, a situation called maternal uniparental disomy.5PubMed Central. Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology A small remaining percentage results from errors in the imprinting centre itself or from rare chromosomal rearrangements.
The syndrome is characterized by weak muscle tone and feeding difficulties in infancy, followed by an insatiable appetite and progressive obesity starting in early childhood. Intellectual disability, short stature, behavioral problems, and incomplete sexual development are also typical. Prader-Willi was one of the first human conditions recognized as an imprinting disorder, which made it an important test case for understanding how parent-of-origin effects work in human genetics.
One unusual route to Prader-Willi involves what is called trisomy rescue. If a fertilized egg starts out with three copies of chromosome 15 instead of two, the developing embryo sometimes corrects itself by discarding one copy. If the copy discarded happens to be the father’s, the child ends up with two maternal copies and develops Prader-Willi syndrome through uniparental disomy.6PubMed. Noninvasive prenatal testing suggesting an abnormality in chromosome 15 confirmed to be a case of Prader-Willi syndrome caused by trisomy rescue in the neonatal period
Angelman Syndrome
Angelman syndrome is essentially the mirror image: it results from the loss of the maternal contribution to the same 15q11-q13 region. The critical gene here is UBE3A, which encodes a protein involved in tagging other proteins for disposal. In neurons, the paternal copy of UBE3A is normally silenced by a long non-coding RNA called UBE3A-ATS. So when the maternal copy is deleted or mutated, brain cells end up with almost no UBE3A protein at all.7Nature Communications. Ube3a unsilencer for the potential treatment of Angelman syndrome
The clinical picture is quite different from Prader-Willi. People with Angelman syndrome typically have severe intellectual disability, minimal or no speech, a characteristic happy demeanor with frequent laughter, seizures, and a distinctive jerky gait. The fact that two such different conditions arise from disruptions in the same chromosomal neighborhood, simply depending on which parent’s genes are affected, made the 15q11-q13 region a landmark example in the study of epigenetic regulation.
The region also contains a cluster of three GABA receptor genes, GABRB3, GABRA5, and GABRG3, which play roles in how the brain’s inhibitory signaling system works. Deletions or duplications affecting these genes have been linked not only to Prader-Willi and Angelman syndromes but also to some cases of autism.8PubMed Central. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders Early case reports documented children with duplications of 15q11-13 on the maternally derived chromosome who presented with autism, epilepsy, and difficulty coordinating movement.9PubMed. Duplication of the 15q11-13 region in a patient with autism, epilepsy and ataxia
Eye Color and Skin Pigmentation
One of the most visible traits influenced by chromosome 15 is eye color. The OCA2 gene, located on 15q, produces a protein that helps regulate the pH inside melanosomes, the cellular compartments where pigment is made. Mutations in OCA2 can cause oculocutaneous albinism type II, a condition involving very light skin, hair, and eyes. But even among people without albinism, normal variation in OCA2 activity is the biggest single genetic factor in determining whether your eyes are brown, blue, or somewhere in between.
The regulation of OCA2 is itself controlled by a neighboring gene on chromosome 15 called HERC2. A specific variant in a HERC2 enhancer region, known to researchers as rs12913832, acts as a dimmer switch for OCA2 expression. The ancestral version of this variant allows a loop of DNA to form between the enhancer and the OCA2 promoter, boosting melanin production and resulting in darker eye color. The derived version weakens that loop, cutting melanin production and strongly predisposing a person to blue eyes.10PubMed Central. Association between Variants in the OCA2-HERC2 Region and Blue Eye Colour in HERC2 rs12913832 AA and AG Individuals The HERC2/OCA2 region on chromosome 15 has the strongest effect on eye color variation of any spot in the genome, strong enough that early researchers treated blue eyes as a simple single-gene trait before realizing other genes also contribute.11iScience. Investigating the genetic architecture of eye colour in a Canadian cohort
Interestingly, this same variant has a much smaller effect on skin and hair pigmentation than it does on the iris. Across African populations, additional variants in the OCA2/HERC2 region have been identified that influence skin color along different evolutionary paths. Some of these variants appear to have been maintained at intermediate frequencies for a long time, suggesting long-term balancing selection, where having a mix of alleles in a population offers some advantage.12Human Molecular Genetics. Evolutionary genetics of skin pigmentation in African populations
Marfan Syndrome and Connective Tissue
Chromosome 15 also carries the FBN1 gene, which encodes fibrillin-1, a large protein that polymerizes into microfibrils. These microfibrils are structural scaffolding for elastic tissues throughout the body, including the walls of blood vessels, the ligaments that hold the lens of the eye in place, and the connective tissue supporting bones and joints. When FBN1 is mutated, the result is Marfan syndrome, a disorder marked by tall stature with unusually long limbs and fingers, dislocation of the eye’s lens, and dangerous weakening of the aorta that can lead to aneurysm and dissection.13PubMed Central. FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders
More than a thousand different mutations in FBN1 have been linked to Marfan syndrome, which makes it difficult to predict how severe a specific case will be based on the genetic change alone. In at least one documented family, the syndrome was caused not by a point mutation within FBN1 but by a chromosomal translocation that physically disrupted the gene, with the breakpoint falling within one of FBN1’s introns on chromosome 15.14PubMed Central. Marfan Syndrome Caused by Disruption of the FBN1 Gene due to A Reciprocal Chromosome Translocation That case illustrated how structural rearrangements, not just small mutations, can knock out a chromosome 15 gene and produce the same clinical picture.
Tay-Sachs Disease
The HEXA gene on chromosome 15 encodes the alpha subunit of an enzyme called beta-hexosaminidase A. This enzyme works inside lysosomes, the cellular recycling centers, to break down a fatty substance called GM2 ganglioside that is abundant in nerve cells. When both copies of HEXA are mutated and the enzyme is absent or deficient, GM2 ganglioside accumulates in the brain, progressively destroying neurons. The result is Tay-Sachs disease, one of the best-known inherited neurological conditions.15PubMed Central. Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India The gene was confirmed to map to chromosome 15 through studies using human-rodent cell hybrids.16Journal of Biological Chemistry. Isolation of cDNA clones coding for the alpha-subunit of human beta-hexosaminidase
In its classic infantile form, Tay-Sachs causes developmental regression, seizures, blindness, and death in early childhood. Mouse models engineered to lack the Hexa gene accumulate GM2 ganglioside in the brain in an age-dependent pattern, developing the same characteristic cellular damage seen in affected children.17PubMed. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease Those models have been essential for developing potential treatments. Gene therapy using viral vectors to deliver working copies of both the alpha and beta subunits of hexosaminidase into the brain has shown promising results in animal studies, delaying symptom onset and reducing the buildup of GM2 ganglioside in mice and sheep.18PubMed Central. Effective gene therapy in an authentic model of Tay-Sachs-related diseases19PubMed. Adeno-Associated Virus Gene Therapy in A Sheep Model of Tay-Sachs Disease Early human trials have since begun, with two children receiving viral vector therapy at different ages and through different delivery routes.20PubMed Central. AAV gene therapy for Tay-Sachs disease
The 15q13.3 Microdeletion and Neuropsychiatric Risk
A separate region farther along the long arm, 15q13.3, is home to a 1.5-million-base-pair stretch that occasionally gets deleted on one chromosome. This microdeletion removes seven genes, among which CHRNA7, encoding a nicotinic acetylcholine receptor subunit involved in brain signaling, has attracted the most attention.21PubMed Central. 15q13.3 homozygous knockout mouse model display epilepsy-, autism- and schizophrenia-related phenotypes People carrying the deletion have increased risk for intellectual disability, epilepsy, autism spectrum disorder, and schizophrenia, though the clinical picture varies widely and some carriers have no obvious symptoms at all.22Journal of Medical Genetics. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders
The epilepsy connection is especially striking. In a study comparing over 1,200 individuals with common forms of epilepsy to nearly 3,700 controls, the 15q13.3 microdeletion showed up exclusively in the epilepsy group, making it the most prevalent known genetic risk factor for common epilepsies at the time of that analysis.23Nature Genetics. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy The incomplete penetrance of this deletion, the fact that not everyone who carries it develops a neuropsychiatric condition, is a reminder that genetic risk factors on chromosome 15 do not act in isolation. Other genes, environmental factors, and chance all shape whether the risk translates into symptoms.
Chromosome 15 and Leukemia
Chromosome 15 plays a role in one of oncology’s most treatable success stories. Acute promyelocytic leukemia, a subtype of acute myeloid leukemia, is defined by a translocation between chromosomes 15 and 17. This swap fuses the PML gene on chromosome 15 with the RARA gene on chromosome 17, creating a PML-RARA fusion protein that jams the normal maturation process of white blood cells, trapping them at an immature promyelocyte stage.24PubMed. Acute promyelocytic leukaemia and the t(15;17) translocation This translocation is found in about 95% of acute promyelocytic leukemia cases.25PubMed Central. Acute promyelocytic leukemia (APL): a review of the literature
The reason this matters beyond genetics is that the fusion protein responds to treatment with all-trans retinoic acid, a derivative of vitamin A that forces the stuck promyelocytes to resume maturing. Before this treatment was discovered, acute promyelocytic leukemia was one of the most dangerous blood cancers, partly because it causes severe bleeding problems. With retinoic acid combined with other therapies, it became one of the most curable forms of leukemia. The chromosome 15-17 translocation is both the cause of the disease and the reason the disease is treatable, a connection that made it a landmark finding in cancer biology.
Heart Muscle and the ACTC1 Gene
Chromosome 15 also carries ACTC1, the gene encoding cardiac alpha-actin, a core structural protein in heart muscle cells. Actin filaments are part of the contractile machinery that allows the heart to pump, and mutations in ACTC1 can cause the heart muscle to grow abnormally thick, a condition called hypertrophic cardiomyopathy.26PubMed Central. Classifying Cardiac Actin Mutations Associated With Hypertrophic Cardiomyopathy Other mutations in the same gene have been linked to dilated cardiomyopathy, where the heart chambers enlarge and weaken, and to a structural abnormality called left ventricular noncompaction.27PubMed Central. Novel α-Actin Gene Mutation p.(Ala21Val) Causing Familial Hypertrophic Cardiomyopathy, Myocardial Noncompaction, and Transmural Crypts These are relatively rare causes of inherited heart disease, but they illustrate how a single gene on chromosome 15 can affect an organ far removed from the brain, where so many other chromosome 15 conditions make themselves felt.
Emerging Therapies Targeting Chromosome 15 Genes
Because several chromosome 15 disorders involve genes that are silenced rather than permanently destroyed, researchers have been exploring ways to wake up the dormant copy. The most advanced approach for Angelman syndrome uses antisense oligonucleotides, short synthetic stretches of modified genetic material designed to block the UBE3A-ATS transcript that silences the paternal copy of UBE3A in neurons. In mouse models of Angelman syndrome, a single injection into the central nervous system at an early age restored UBE3A protein to roughly three-quarters of normal levels in the cortex and fully prevented sensitivity to a specific type of seizure. Mice treated soon after birth also showed improvements in movement and behavior on standard laboratory tests.28PubMed Central. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model
For Tay-Sachs disease, the strategy is different because the problem is a missing enzyme rather than a silenced gene. Here, gene therapy aims to deliver working copies of the HEXA and HEXB genes directly into the brain using viral vectors. Animal studies in both mice and sheep have shown that this approach can restore enzyme activity widely across the nervous system and delay disease onset.18PubMed Central. Effective gene therapy in an authentic model of Tay-Sachs-related diseases Human trials are still in early stages, but the trajectory from bench to bedside has been faster for chromosome 15 disorders than for many other genetic conditions, partly because the molecular targets are so well defined. The recurring theme across all of these efforts is that chromosome 15’s unusual biology, particularly its reliance on imprinting and parent-of-origin expression, creates both the vulnerability that causes disease and the therapeutic opening that may one day allow treatment.